ZYKADIA™ (ceritinib) - Cancer Therapy Advisor

ZYKADIA™ (ceritinib)

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for ZYKADIA™ (ceritinib), indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 9: Use in Specific Populations
Slide 11: Clinical Pharmacology
Slide 15: Warnings and Precautions
Slide 19: Clinical Safety and Efficacy
Slide 24: Drug Storage and Supply

Next hm-slideshow in Slides